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Thrombolysis in Arterial Graft Thrombosis 
D. C. Berridge, A. AI-Kutoubi, A. O. Mansfield, A. N. Nicolaides and J. H. N. Wolfe 
Academic Surgical Unit and Regional Vascular Unit, St Mary's Hospital, Praed Street, London W2 1NY, U.K. 
Objective: to assess the impact of peripheral arterial thrombolysis for vascular graft occlusion. 
Design: Retrospective r view. 
Setting: University Hospital. 
Materials: Thirty-one patients presented with 33 episodes of graft thrombosis. 
Chief outcome measures: Successful thrombolysis in terms of total clearance or sufficient clearance to reveal an 
underlying factor responsible for graft failure. 
Main results: Thrombolysis was successful in seven of 10 suprainguinal grafts (4 of 5 rtPA; 3 of 5 SK). One patient had 
failed tysis requiring an ilio-femoraI graft. Of the seven patients with successful Iysis, one required revision of a. proximal 
anastomosis, two required distal anastomotic revisions, and one rethrombosed. Twenty-three thrombosed infrainguinal 
grafts were managed initially with intraarterial thrombolysis (9rtPA, 14 SK). 0 f27 patients urviving at 30 days, seven 
required major amputation despite aggressive intervention. 
Conclusions: Thrombosed suprainguinal grafts are amenable to thrombolysis and adjunctive surgery when necessary, 
with no major haemorrhagic complications. The majority of patients with thrombosed infrainguinal grafts require surgical 
intervention in order to preserve, or establish long term patency. For polytetrafluorethylene (PTFE) grafts, thrombolysis 
was associated with poor success, haemorrhagic omplications and a high amputation rate. 
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Introduction Methods 
Whilst peripheral arterial thrombolysis has become 
established as both a diagnostic and therapeutic tool 
in the management of arterial disease, its role in graft 
thrombolysis i less clear cut. Lysis within a Dacron 
graft has the potential hazard of haemorrhage through 
the graft wall. 1 Similarl~ early experience with throm- 
bolysis of thrombosed polytetrafluoroethylene grafts 
(PTFE) often served only to reveal progression of 
distal disease, with no further benefit to the patient 
and was associated with early re-thrombosis on 
withdrawal of the intraarterial catheter. Unless lysis 
could be established within 24 hours of occlusion of a 
vein graft, it was felt that the resultant endothelial cell 
damage would ensure that whatever patency was 
achieved would only be short-lived. We therefore 
reviewed all patients treated with peripheral arterial 
thrombolysis for graft occlusion in this institution over 
a 6-year period from October 1987 to September 
1993. 
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All patients presenting with graft thromboses to the 
Regional Vascular Unit over the period of October 
1987 to September 1993 were considered for intra- 
arterial thrombolysis. Patients with an established 
motor or sensory deficit Were considered unsuitable 
for lysis and were offered reconstructive surgery 
whenever possible. Thirty-one patients with 33 epi- 
sodes of graft thrombosis were treated. The median 
duration of history of occlusion was 2 days (range 
1-21). Most patients presented with rest pain and 
critical ischaemia, but five patients presented with 
severe claudication. Suprainguinal grafts were lysed 
either directly into the graft or via a brachial artery 
approach. A contralateral femoral artery approach 
was the standard administration site for infrainguinal 
grafts. During the early part of the audit period, 
streptokinase (SK; Kabikinase, KabiVitrum, Uxbridge) 
was administered at 5,000 IU/h intraarterially in 
conjunction with heparin 250 IU/h intraarterially. 
Most recently the standard lytic agent was changed to 
recombinant tissue plasminogen activator (rt-PA; Alte- 
plase, Boehringer Ingelheim, Bracknell) at a dose of 0.5 
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to 1 mg/h intraarterially, again in combination with 
250 IU/h of intraarterial heparin. All patients were 
nursed in the Vascular High Dependency Unit with 
repeat arteriograms performed within the vascular 
radiological suite. Lysis was deemed successful if 
either total clearance of the occlusion was achieved, or 
sufficient clearance to reveal an underlying aetio- 
logical factor responsible for graft failure. 
Results 
Suprainguinal grafts (Fig. 1) 
Ten patients (4 male, 6 female) with a mean age of 59 
+ 16 years presented with suprainguinal graft throm- 
Table 1. 30-day outcome following graft thrombolysis 
30 Day Suprainguinal Infrainguinal PTFE 
Dacron Vein 
n=10 n=8 n=15 
Success lysis alone 4 4 2 
Success lysis + surgery 3 2 2 
Failure of lysis, 1 0 4 
successful reconstruction 
Amputation 1 1 5 
Died 1 1 2 
boses (Table 1). Suprainguinal grafts (Dacron) had 
been implanted a median of 3 years previously (range 
3 months to 22 years), one patient suffered severe 
claudication, the remaining nine patients presenting 
with rest pain. The median duration of history was 3 
days with a range of 1-7 days. Six patients had had an 
aortobifemoral graft, three an iliofemoral graft and 
one patient an iliopopliteal graft. Thrombolysis was 
initially successful in nine (90%) of suprainguinal 
grafts; however, two patients underwent rethrombo- 
sis, one of whom required a below-knee amputation. 
No further reconstruction was attempted in the 
second patient as he had very poor left ventricular 
function and the presence of an ischaemic but viable 
limb. 
Infrainguinal grafts (Figs. 2, 3) 
Infrainguinal grafts (8 vein, 15 PTFE) were performed 
a median of 1 year previously (8 days-11 years). The 
mean age of the patients was 58 + 11 years. Four 
patients had claudication whereas the majority experi- 
enced rest pain on occlusion of the graft. The median 
duration of history was 3 days With a range of 1-21 
days. Twenty-three thrombosed infrainguinal grafts 
were managed initially with intraarterial thrombolysis 
with rtPA (9) or streptokinase (14). 
/ 
10 
Supra-inguinal grafts 
Dacron n=10 1 died - acute renal failure 
stercoral perforation 
of sigmoid colon 
5 rtPA-- successful 1 no further 
lysie ~ ~ ~ treatment 
1 distal 1 patch engioplasty 1 rethrombosed 
anastomotic of proximal 
revision anastomosis 
1 bilateral anastomotic 
revision / 
4 successful / 2 no further 
5SK Nys is  ~ treatment 
no lysis 1 =mmediate r thromb0sis 
ilio-femoral N 
graft f below-knee amputation 
Fig. 1. Flow diagram showing outcome following suprainguinal 
graft lysis. 
Infra-inguinal grafts 
Vein n=8 
fern-distal -- BKA 
/ 
1 failure of lysis 1 distal patch 1 re-thrombosis 
(claudicant no surgery) angioplasty /day 7 
~ 1 rethrombosis 
retreated successfully 
~lSKaj°r h a ,~ rrhage) /Thrombolys i s  
5 success 2 no further 
treatment 
21rtPA success 2 distal jump grafts 1 no further major haemorrhage) ~ treatment 
1 died 
Fig. 2. Flow diagram showing outcome following infrainguinal vein 
graft lysis. 
Infra-inguinal grafts 
Polytet raft uoroet hylene n=15 
1 successful reconstruction 
2 failed l y s i s ~  
J ~ 1 above-knee amputation 
/ 7rtPA 1 no further treatment \ \ 
3 distal jump grafts 1 further femoro-popliteal reconstruction 
1 aistal jump graft --  AKA -- Died 
/ _ 8SK 1 no further treatment 
5 failed lysis 
I 1 successful reconstruction - -  re-thrombosis 
5 reconstructed I / \ BKA--AKA 
2 above-knee amputations 3 successfu~ 
/ \ 
1 died 1 Successful 
Fig. 3. Flow diagram showing outcome following infrainguinal 
PTFE graft lysis. 
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Lysis was initially successful in seven of eight 
vein grafts, three of which required istal anastomotic 
revision (one vein patch angioplasty, two jump grafts), 
one of whom developed renal failure and died. Two 
re-thromboses occurred, one was re-cannalised with a 
further course of lytic therap3~ the second requring a 
femorodistal reconstruction which subsequently 
failed, resulting in a below knee amputation. One 
patient had no discernible lysis achieved. 
Of 15 prosthetic grafts, seven failed lysis, one of 
whom required an above-knee amputation, six were 
reconstructed but two patients till required above- 
knee amputations, one of whom died. Seven patients 
underwent successful lysis of their grafts, four of 
which required istal jump grafts, and one required a
repeat femoropopliteal graft. Three patients re-throm- 
bosed, two requiring below-knee amputation (one 
died) and one subsequently underwent 
reconstruction. 
Major complications 
Despite aggressive intervention, seven patients in total 
required major amputation [one suprainguinal (13%), 
six (26%) infrainguinal grafts]. Haemorrhagic compli- 
cations were few, with four major haemorrhages - -  
all in patients with infrainguinal grafts. Four patients 
died within 30 days, all had prosthetic graft throm- 
boses. Two died from myocardial infarctions, and two 
patients died after developing renal failure, acidosis 
and cardiac failure. 
Discussion 
Whilst intervention for a "failing" graft is associated 
with a high success rate in terms of graft patency and 
limb salvage, 2 the management of a thrombosed graft 
presents a greater challenge with an associated higher 
morbidity and mortality. 3' 4 Initial reports of percuta- 
neous thrombolysis and secondary reconstruction, 
showed promising short-term results,  although long- 
term patency was less encouraging. 6 Some therefore 
question the value of graft lysis and consider that it 
would be more beneficial to insert a new graft or 
indeed to perform a primary amputation. 7 
Using high dose urokinase infusions, Arnold et 
al. 8 achieved complete thrombolysis n 27 of 41 (61%) 
graft occlusions; of these 20 (74%) subsequently 
required surgical reconstruction. They found that 1 
year patency following complete thrombolysis and 
appropriate reconstruction (54%) was better than that 
for complete thrombolysis alone (34%), or incomplete 
lysis necessitating reconstruction (38%); a similar 
trend was found at 1 year. 
Similarly, in a retrospective comparison between 
surgery and thrombolysis followed by surger~ 
improved 30-day patency was observed in the com- 
bined therapy group, s Patients with rtPA had an 86% 
30-day graft patency compared to 42% of the surgi- 
cally treated grafts (p = 0.001). Both groups required 
secondary revisional surgery in 90% of cases. 
Thrombolysis for occluded Dacron grafts, espe- 
cially retroperitoneal grafts, has the added theoretical 
risk of uncontrollable haemorrhage through the inter- 
cises of the graft. 1' 9 Experience is therefore limited. 
Whether this risk is altered by the type of Dacron 
graft, for example knitted > woven > sealed is 
unknown, and the influence of the maturity of the 
graft can only be surmised. Our own experience often 
patients, although small, has shown very encouraging 
lysis with no major haemorrhagic omplications 
incurred. 
Encouraging results for the use of thrombolysis in
occluded vein grafts have also been reported by 
Patterson et al. 1° Lysis was successful in 28 patients 
within 24 hours allowing appropriate surgical inter- 
vention to 18 underlying stenoses and seven patients 
with progression of distal disease. Overall secondary 
revascularisation was achieved in 58% of patients. 
These results are similar to our own experience in vein 
graft thromboses. Only two of eight patients (25%) 
were successfully lysed with no further adjuvant 
treatment necessary. Whilst graft thrombosis was 
attempted up to 21 days post-occlusion, the median 
duration of history of three days was considerably 
shorter than in the Birmingham series. 1° 
Prosthetic grafts proved more recalcitrant. Only 
one patient underwent successful lysis with no adju- 
vant treatment. Initial lysis failed in seven (47%), 
despite subsequent surgical reconstruction wherever 
possible in all patients; five above-knee amputations 
were eventually required, of which two patients died 
within the period of follow-up. 
It is a fundamental pre-requisite for long term 
patency to correct any underlying lesion. Gardiner et 
al. 11 report an 86% 1-year patency in patients with 
successfully sed grafts with a correctable aetiological 
lesion, compared to only 37% 1-year patency in those 
without a correctable l sion. Newer techniques such 
as pulse-spray 12 or high dose bolus administra- 
tion 13' !4 may facilitate the application of thrombolysis 
for the more acute cases which would otherwise not 
be amenable to percutaneous low dose infusion. 
However, the potential benefits should always be 
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balanced against he danger of rapid but only partial 
lysis of the thrombosis, which may result in distal 
embolisation. The choice of agent should allow the 
safest surgical intervention with the minimum of 
systemic effect. 15 
Thrombosed suprainguinal grafts proved to be 
amenable to thrombolysis and adjunctive surgery 
when necessary with no major haemorrhagic compli- 
cations. At least 50% of patients will require spe- 
cialised radiological or surgical intervention i  order 
to preserve or establish long term patency following 
thrombolysis for graft thrombosis. Percutaneous 
thrombolysis was less successful in infrainguinal 
PTFE graft thromboses, despite surgical reconstruc- 
tion wherever possible. This series highlights the need 
for a team approach in patients with graft thromboses: 
thrombolysis has proved a useful adjunctive measure 
in our patients with graft occlusion, but alone is only 
successful in approximately a quarter of patients. With 
further surgical intervention a further quarter of grafts 
are salvaged. Despite aggressive intervention, seven 
major amputations (21%) were still required, under- 
lying the serious nature of graft occlusion in patients 
formerly with critical ischaemia. 
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